SCHEMBL27175809

SCHEMBL27175809

CC(C)(C)OC(=O)N1CCC(F)(c2ccc(N)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.48
BACE1 P56817 2/20 0.46
CTSD P07339 1/20 0.46
CTSE P14091 1/20 0.46
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
ATM Q13315 1/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC1 Q13547 1/20 0.43
ALDH1A1 P00352 2/20 0.43
TACR1 P25103 1/20 0.43
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RORC P51449 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778727 0.88 RORC (0.51) TSHRALOX15ATMHDAC2HDAC1
SCHEMBL1200040 0.86 RORC (0.53) BACE1CTSDCTSETSHRALOX15
SCHEMBL2588263 0.86 MEN1 (0.55) TSHRALOX15ATMTACR1OPRD1
SCHEMBL237234 0.86 TSHR (0.56) TSHRALOX15ATMTACR1OPRD1
SCHEMBL15961875 0.85 KMT2A (0.45) BACE1CTSDCTSETSHRALOX15
SCHEMBL16764329 0.85 NR1H2 (0.49) NR1H2BACE1CTSDCTSETSHR
SCHEMBL15379660 0.85 NR1H2 (0.49) NR1H2BACE1CTSDCTSETSHR
SCHEMBL24833030 0.83 TACR1 (0.50) NR1H2BACE1CTSDCTSETSHR
SCHEMBL5462841 0.83 GPR119 (0.53) ALDH1A1MAPK1
SCHEMBL15961874 0.80 ATM (0.48) ATMHDAC1ALDH1A1TACR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360146-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2024-10-31 US disclosed
EP-4342892-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2024-03-27 EP disclosed
WO-2023274390-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF 杭州和正医药有限公司 2023-01-05 WO disclosed
CN-115557933-A Bruton tyrosine kinase and mutant degradation agent, composition and application thereof 杭州和正医药有限公司 2023-01-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360146-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF BTK, ZAP70, SYK NR1H2 3113/4885BACE1 1927/4885CTSD 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.